top of page

Free Biopharma Daily Stock Updates - 07/15/21

  • Writer: BPIQ
    BPIQ
  • Jul 15, 2021
  • 1 min read

$XBI $125.9 -0.01%

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Covid Updates

$CRVS -1.7% Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations. source


$OCGN -1.2% Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN™. source


Pipeline Updates

$RVVTF 0% Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19. source


$DNLI +0.4% Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021. source


$VIR +2.4% Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection. source


$RUBY +3.3% Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy. source


$BCRX +1.1% BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH. source


$ARAV -1.5% Aravive Achieves Second Development Milestone from 3D Medicines. source


$SYBX +6.1% Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU). source


$XOMA 0.3% XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences. source


$TMDX -2.1% TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System. source


$GLPG -13.0% On 7/14 Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study. source




Financial Updates

$IMV -28.9% IMV Inc. Announces Pricing of Public Offering. source


$IMUX -21.5% Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock. source


Posted by FS

 
 
 

Comments

bottom of page